SCHEMBL979299

SCHEMBL979299

COc1ccc(C2=NN(C(=O)Cc3ccc(O)cc3)CC2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.65
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PDE4B Q07343 11/20 0.47
PDE4D Q08499 4/20 0.45
PDE4A P27815 3/20 0.45
PDE4C Q08493 3/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
HTT P42858 1/20 0.45
ABCB1 P08183 2/20 0.44
ABCC1 P33527 2/20 0.44
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981326 0.91 MAOB (0.65) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL981491 0.90 MAOB (0.64) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL979373 0.90 MAOB (0.67) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL980754 0.88 MAOB (0.61) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3327514 0.87 ALDH1A1 (0.51) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3323922 0.86 ALDH1A1 (0.51) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3323955 0.85 MAOB (0.57) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3324086 0.84 MEN1 (0.50) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL980757 0.84 MAOB (0.61) MAOBALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL6601466 0.84 MAOB (0.56) MAOBALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 MAOB 1138/4885ALDH1A1 399/4885HPGD 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.